POLE is altered in 3.65% of malignant solid tumor patients with POLE Loss present in 0.03% of all malignant solid tumor patients [4].

POLE Loss is an inclusion criterion in 20 clinical trials for malignant solid tumor, of which 18 are open and 2 are closed. Of the trials that contain POLE Loss and malignant solid tumor as inclusion criteria, 8 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 8 are phase 2 (8 open) [5].

POLE is altered in 2.42% of prostate adenocarcinoma patients with POLE Loss present in 0.13% of all prostate adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain POLE Loss and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [5].

POLE is altered in 9.25% of endometrial carcinoma patients with POLE Loss present in 0.05% of all endometrial carcinoma patients [4].

POLE Loss is an inclusion criterion in 7 clinical trials for endometrial carcinoma, of which 7 are open and 0 are closed. Of the trials that contain POLE Loss and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

POLE is altered in 2.5% of prostate carcinoma patients with POLE Loss present in 0.13% of all prostate carcinoma patients [4].

POLE Loss is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain POLE Loss and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

POLE is altered in 1.66% of ovarian carcinoma patients with POLE Loss present in 0.05% of all ovarian carcinoma patients [4].

POLE Loss is an inclusion criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain POLE Loss and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

POLE is altered in 2.0% of breast carcinoma patients with POLE Loss present in 0.02% of all breast carcinoma patients [4].

POLE Loss is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain POLE Loss and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [5].

POLE is altered in 5.63% of colorectal carcinoma patients with POLE Loss present in 0.05% of all colorectal carcinoma patients [4].

POLE Loss is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain POLE Loss and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

POLE is altered in 3.18% of cervical carcinoma patients [4].

POLE Loss is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain POLE Loss and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

POLE is altered in 4.19% of non-small cell lung carcinoma patients [4].

POLE Loss is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain POLE Loss and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

POLE is altered in 3.56% of adenocarcinoma of the gastroesophageal junction patients [4].

POLE Loss is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain POLE Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

POLE is altered in 4.55% of primary peritoneal carcinoma patients [4].

POLE Loss is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain POLE Loss and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 5.49% of bladder carcinoma patients with POLE Loss present in 0.07% of all bladder carcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Loss and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

POLE is altered in 1.52% of high grade ovarian serous adenocarcinoma patients with POLE Loss present in 0.07% of all high grade ovarian serous adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain POLE Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

POLE is altered in 2.72% of head and neck carcinoma patients with POLE Loss present in 0.06% of all head and neck carcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Loss and head and neck carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

POLE is altered in 6.08% of urothelial carcinoma patients with POLE Loss present in 0.06% of all urothelial carcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Loss and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

POLE is altered in 5.69% of colorectal adenocarcinoma patients with POLE Loss present in 0.05% of all colorectal adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Loss and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

POLE is altered in 1.46% of soft tissue sarcoma patients with POLE Loss present in 0.05% of all soft tissue sarcoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain POLE Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

POLE is altered in 3.19% of central nervous system neoplasm patients with POLE Loss present in 0.02% of all central nervous system neoplasm patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain POLE Loss and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 1.82% of fallopian tube carcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Loss and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

POLE is altered in 2.56% of gastric carcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Loss and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 3.65% of head and neck squamous cell carcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain POLE Loss and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

POLE is altered in 1.62% of non-hodgkin lymphoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain POLE Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

POLE is altered in 1.52% of pancreatic carcinoma patients [4].

POLE Loss is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

POLE is altered in 2.22% of uterine corpus carcinosarcoma patients with POLE Loss present in 0.4% of all uterine corpus carcinosarcoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 4.32% of small cell lung carcinoma patients with POLE Loss present in 0.23% of all small cell lung carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 1.11% of malignant salivary gland neoplasm patients with POLE Loss present in 0.21% of all malignant salivary gland neoplasm patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 6.97% of malignant uterine neoplasm patients with POLE Loss present in 0.1% of all malignant uterine neoplasm patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 8.41% of melanoma patients with POLE Loss present in 0.09% of all melanoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 5.91% of bladder urothelial carcinoma patients with POLE Loss present in 0.07% of all bladder urothelial carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 8.79% of endometrial adenocarcinoma patients with POLE Loss present in 0.06% of all endometrial adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and endometrial adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 5.7% of malignant intestinal neoplasm patients with POLE Loss present in 0.05% of all malignant intestinal neoplasm patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 1.69% of malignant ovarian epithelial tumor patients with POLE Loss present in 0.05% of all malignant ovarian epithelial tumor patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 3.62% of cancer patients with POLE Loss present in 0.03% of all cancer patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 4.19% of lung carcinoma patients with POLE Loss present in 0.01% of all lung carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for adnexal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and adnexal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 2.17% of ampulla of vater carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 3.73% of anal carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE Loss and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

POLE is altered in 1.67% of B-cell non-hodgkin lymphoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 13.73% of basal cell carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and basal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 2.75% of bile duct carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 2.75% of cholangiocarcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 2.34% of diffuse large B-cell lymphoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 1.14% of endometrial serous adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 16.67% of endometrial undifferentiated carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for endometrial undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and endometrial undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 3.57% of esophageal carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 3.23% of esophageal squamous cell carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 2.2% of gallbladder carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 2.58% of gastric adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 0.86% of gastrointestinal stromal tumor patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 1.82% of high grade fallopian tube serous adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 1.59% of lymphoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 3.37% of malignant esophagogastric neoplasm patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 2.56% of malignant gastric neoplasm patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE is altered in 7.82% of malignant small intestinal neoplasm patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 1.65% of mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 3.33% of multiple myeloma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 1.55% of non-clear cell renal cell carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 3.75% of ovarian endometrioid adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 1.51% of pancreatic adenocarcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE is altered in 5.56% of penile carcinoma patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE Loss and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for primary peritoneal clear cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and primary peritoneal clear cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE is altered in 5.56% of squamous cell carcinoma of the penis patients [4].

POLE Loss is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains POLE Loss and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE Loss and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

POLE Loss is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE Loss and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].